Attorney Docket No.: 015280-478100US DHHS Ref. No.: E-331-2002/0-US-03

DHHS Řef. No.: E-331-2002/0-US-03 PTO/SB/01A (07-06)

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	ACTIVATION OF RECOMBINANT DIPHTHERIA TOXIN PROTEASES HIGHLY EXPRESSED ON THE SURFAC			
As the below	v named inventor(s), I/we declare that:			
This declara	tion is directed to:			
	The attached application, or	·		
	Application No. <u>10/554,076</u> ,	filed on October 21, 2005		
	as amended on	(if applicable);		
l/we believe sought;	I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;			
	viewed and understand the contents of the above-identified appli specifically referred to above;	cation, including the claims, as amended by any		
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.				
WARNING: Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioner/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an Issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available. All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon:				
FULL NAM	E OF INVENTOR(S)			
Inventor on	e: Stephen H. Leppla	Citizen of: United States		
Signature:	Sten Legga	Date: 21 MARK 7007		
Inventor two	o: Jennifer Avallone	Citizen of: United States		
Signature:		Date:		
Addition	nal inventors or a legal representative are being named on	1additional form(s) attached hereto.		

Attorney Docket No.: 015280-478100US

DHHS Ref. No.: E-331-2002/0-US-03 PTO/SB/01A (07-08)

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	ACTIVATION OF RECOMBINANT DIPHTHERIA TOXIN PROTEASES HIGHLY EXPRESSED ON THE SURFACI			
As the below	v named inventor(s), I/we declare that:	'		
This declara	tion is directed to:	·		
	The attached application, or			
	Application No. <u>10/554,076</u> , fi	iled on October 21, 2005		
	as amended on	(if applicable);		
I/we believe sought;	I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;			
	I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;			
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.				
WARNING: Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioner/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available. All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon:				
FULL NAM	E OF INVENTOR(S)			
Inventor on	e: Stephen H. Leppla	Citizen of: United States		
Signature:		Date:		
Inventor two	o: Jennifer Avallone	Citizen of: United States		
Signature:	genniser ovallone	Date: 4/18/07		
Addition	nal inventors or a legal representative are being named on1	additional form(s) attached hereto.		

Attorney Docket No.: 015280-478100US Client Ref. No.: E-331-2002/0-US-03

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76) – ADDITIONAL INVENTOR(S) Supplemental Sheet 1 of 1

FULL NAME OF INVENTOR(S)				
Inventor three: Signature:	Themas Bugge	Citizen of:	Denmark 3/21/07	
Inventor four: Signature:	Shi-Hui Liu	Citizen of: Date:	China	
Inventor five: Signature:	Manuel Osorio		United States	
Inventor six: Signature:		- · - · ·		
Inventor eight:		Citizen of:		
Inventor nine: Signature:				
Inventor ten: Signature:				
Inventor twelve:		Citizen of:		

Attorney Docket No.: 015280-478100US Client Ref. No.: E-331-2002/0-US-03

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76) — ADDITIONAL INVENTOR(S) Supplemental Sheet 1 of 1

FULL NAME OF	INVENTOR(S)		
Inventor three: Signature:	Thomas Bugge	Citizen of: Date:	Denmark
Inventor four: Signature:	Shi-Hui Liu	Citizen of: Date:	China 21 March, 2007
Inventor five: Signature:	Manuel Osorio	-	United States
Inventor six: Signature:			
Inventor nine: Signature:			
Inventor ten: Signature:			

Attorney Docket No.: 015280-478100US Client Ref. No.: E-331-2002/0-US-03

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76) – ADDITIONAL INVENTOR(S) Supplemental Sheet 1 of 1

FULL NAME OF INVENTOR(S)	
Inventor three: Thomas Bugge Signature:	Citizen of: Denmark Date:
Inventor four: Shi-Hui Liu Signature:	Citizen of: China Date:
Inventor five: Manuel Osorio Signature: Monuel Osorio	Citizen of: United States Date: 3/29/07
Inventor six: Signature:	Citizen of: Date:
Inventor seven: Signature:	Citizen of: Date:
Inventor eight: Signature:	Citizen of:
Inventor nine: Signature:	Citizen of: Date:
Inventor ten: Signature:	Citizen of: Date:
Inventor eleven: Signature:	Citizen of:
Inventor twelve: Signature:	Citizen of:

	•		Applicat	ion Num	ber	10/554,076	
			Filing Da	ate		October 21, 200	5
			First Na	med Inve	entor	Stephen H. Lepp	ola
POWER OF ATTORNEY OR AUTHORIZATION OF AGENT		Title		ACTIVATION OF RECOMBINANT DIPHTHERIA TOXIN FUSION PROTEINS BY SPECIFIC PROTEASES HIGHLY EXPRESSED ON THE SURFACE OF TUMOR CELLS			
			Art Unit				
			Examine	er Name		,	
			Attorney	/ Docket	Number	015280-478100เ	JS
I hereby appo	int:						
OR		ustomer Number 451	15				
		Name			Registra	ation Number	· ·
		or agent(s) to prosecute the Office connected therewith		n identified	l above, and t	to transact all busine	ss in the United States
Please recogniz	ze or ch	ange the correspondence	address for	the above	e-identified ap	pplication to:	·
☑ The above-r	mention	ed Customer Number.					
OR							
☐ The address	s associ	ated with Customer Numb	er:				
OR						·	
☐ Firm <i>or</i> Individual N	lame						
Address							
Address							
City				State		ZIP	
Country							
Telephone				Fax			
I am the:							
☐ Applicant/Inventor.							
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).							
SIGNATURE of Applicant or Assignee of Record							
Name Tasbic S. Kindra							
Signature	Jasty	Mindry (Reg. 10	.41,119				
	1 %						
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.							
Total of forms are submitted.							

Application No./Patent Owner: Stephen H. Leppla et al. Application No./Patent No.: 10/554,076 Filed/Issue Date: October 21, 2005 Entitled: ACTIVATION OF RECOMBINANT DIPHTHERIA TOXIN FUSION PROTEINS BY SPECIFIC PROTEASES HIGHLY EXPRESSED ON THE SURFACE OF TUMOR CELLS The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services. (Name of Assignee) states that it is: 1. the assignee of the entire right, title, and interest; or 2. an assignee of less than the entire right, title and interest. The extent (by, percentage) of its ownership interest is% in the patent application/patent identified above by virtue of either: A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached. OR B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:				
Entitled: ACTIVATION OF RECOMBINANT DIPHTHERIA TOXIN FUSION PROTEINS RY SPECIFIC PROTEASES HIGHLY EXPRESSED ON THE SURFACE OF TUMOR CELLS The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, (Name of Assignee) states that it is: 1.				
SPECIFIC PROTEASES HIGHLY EXPRESSED ON THE SURFACE OF TUMOR CELLS The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services. (Name of Assignee) States that it is: 1. the assignee of the entire right, title, and interest; or 2. an assignee of less than the entire right, title and interest. The extent (by, percentage) of its ownership interest is% in the patent application/patent identified above by virtue of either: A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached. OR B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as				
America as represented by the Secretary of the Department of Health and Human Services, (Name of Assignee) states that it is: 1.				
 the assignee of the entire right, title, and interest; or an assignee of less than the entire right, title and interest. The extent (by, percentage) of its ownership interest is% in the patent application/patent identified above by virtue of either: An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached. OR A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as 				
 2. an assignee of less than the entire right, title and interest. The extent (by, percentage) of its ownership interest is% in the patent application/patent identified above by virtue of either: A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached. OR B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as 				
The extent (by, percentage) of its ownership interest is% in the patent application/patent identified above by virtue of either: A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached. OR B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as				
 A. \(\text{\texi}\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\tex				
recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached. OR B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as				
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as				
1. From: To :				
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.				
2. From:				
The document was recorded in the United States Patent and Trademark Office at				
Reel, Frame, or for which a copy thereof is attached.				
☐ Additional documents in the chain of title are listed on a supplemental sheet.				
Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]				
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.				
May 10, 2007 Tastirs. Kind/a Typed or printed name				
Date Typed or printed name				
(301) 435-5559 (Jarlin S. / Kindry CReg. 41,115)				
Telephone number Signature				
Technolosy Livensig Spēcialist				

ASSIGNMENT

WHEREAS, We, Stephen H. Leppla of 9501 Starmont Rd., Bethesda, MD, 20817; Jennifer Avallone of 4 Beehive Lane, Flemington, NJ, 08822; Thomas Bugge of 9802 Bristol Square Lane, Apt. 302, Bethesda, MD, 20814; Shi-Hui Liu of 14516 Settlers Landing Way, Gaithersburg, MD, 20878; and Manuel Osorio of 4710 Bethesda Avenue, #706, Bethesda, MD, 20814 employees of the Department of Health and Human Services at the time the invention was made, have invented (title of invention): ACTIVATION OF RECOMBINANT DIPHTHERIA TOXIN FUSION PROTEINS BY SPECIFIC PROTEASES HIGHLY EXPRESSED ON THE SURFACE OF TUMOR CELLS, for which an application to the Commissioner for Patents for grant of Letters Patents of the United States of America has been executed by the undersigned

on (date(s) Declaration signed):

Serial No. 10/554,076

Filed October 21, 2005; and

WHEREAS, the conditions under which said invention was made are such as to entitle the Government of the United States of America under Paragraph 1(a) of Executive Order 10096, to the entire right, title, and interest herein, both domestic and foreign; and

WHEREAS, the Government of the United States of America is desirous of acquiring all domestic and foreign right, title, and interest in the aforesaid invention described in the aforesaid application for Letters Patent of the United States of America; and

NOW, THEREFORE, to all whom it may concern, be it known that for and in consideration of the premises and other valuable considerations, we the undersigned, have sold, assigned, and transferred and by these presents do sell, assign, and transfer unto The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (hereinafter THE GOVERNMENT), and his successors, the full and exclusive right, title, and interest throughout the United States of America, its territories and dependencies, and within each and every foreign country in which THE GOVERNMENT elects to file the invention described in the aforesaid application for Letters Patent of the United States of America, and all Letters Patents and Registrations which may be granted on the same in the United States of America and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

AND, we hereby authorize and request the Commissioner for Patents to issue said Letters Patent to THE GOVERNMENT as assignee of the entire right, title, and interest in and to the same throughout the United States of America, its territories and dependencies, and within each and every foreign country in which THE GOVERNMENT elects to file, for the sole use for the full term or terms for which said Letters Patent and Registrations may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof which may be granted as fully and entirely as the same would have been held by us, had this assignment not been made;

AND, we hereby warrant that there are no outstanding assignments, grants, liens, encumbrances, or agreements either written, oral, or implied with respect to the aforesaid application for Letters Patent which will impair, diminish, limit, or abridge the interest herein conveyed at the time of the execution of this instrument by us;

AND, we hereby agree to execute any and all applications for Letters Patent in the United States of America and foreign countries, and to furnish and deliver to the Secretary, Department of Health and Human Services, upon request, all data and documents, and to execute any papers which may be necessary for the prosecution of any application or applications of Letters Patent or for THE GOVERNMENT to exercise its rights granted hereunder, including communicating to THE GOVERNMENT, its representatives or agents, any facts relating to said invention, including evidence for interference purposes, or for other proceedings, whenever requested, to testify in any interference or other proceedings, whenever requested, and to execute and deliver on request all lawful papers required to make any of the foregoing provisions effective, and likewise make these provisions binding upon our heirs, legal representatives, administrators and assigns, and we shall assist THE GOVERNMENT in every way as may be requested in protecting said invention, provided that any expense of extending such assistance shall be paid by THE GOVERNMENT.

The undersigned hereby grants THE GOVERNMENT or the law firm of Townsend and Townsend and Crew LLP, the power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

TTC file no. 015280-478100US DHHS ref. no. E-264-2006/0-US-01

. IN TESTIMONY WHEREOF, Assignors have signed their names on the dates indicated.

Stephen H. Leppla	1 4 Apr 2007 Date
STATE OF MANY AND COUNTY OF MONTY OF	
to me on the basis of satisfactory evidence) the within instrument and acknowledged to	(here insert name and title of the heir signature(s) on the instrument the person(s), or the ed, execute the instrument.
WITNESS my hand and official seal.	Signature Moudal Mark
(Seal)	Charlene D. Dixon NOTARY PUBLIC Montgomery County, Maryland My Commission Expires 6/1/2010

Jennifer Avallone Jennifer Avallone	ne 4/18/07
STATE OF Hunterdon	
to me on the basis of satisfactory evidence) the within instrument and acknowledged to	(here insert name and title of AVA (love), personally known to me (or proved to be the person(s) whose name(s) is/are subscribed to me that he/she/they executed the same in his/her/thei/their signature(s) on the instrument the person(s), or the ted, execute the instrument.
WITNESS my hand and official seal.	Signature Manda L. Sandar
(Seal)	RHONDA L. SANDAR ID # 2339318 NOTARY PIER COR HOW

Commission Expires 1/19/2011

TTC file no. 015280-478100US DHHS ref. no. E-264-2006/0-US-01

Thomas Bugge	<u> </u>	3/21/07 Date	
Thomas Bugge			
STATE OF Maryland) COUNTY OF Montgomery	·		
UNITED STATES OF AMERICA			•
On March 21, 2007, before me, March 21, 2007, before me, Months officer), personally appeared Thom to me on the basis of satisfactory evidence the within instrument and acknowledged authorized capacity(ies), and that by his/hentity upon behalf of which the person(s)	ce) to be the pers I to me that he/sh ner/their signature	son(s) whose name(s) is/are ne/they executed the same in e(s) on the instrument the per	subscribed to n his/her/their
WITNESS my hand and official seal.	•		
	Signature_	Mille	
	·	MICHAEL LUM	

TTC file no. 015280-478100US DHHS ref. no. E-264-2006/0-US-01

- Inha	n 4/4/07
Shi-Hui Liu	Date
to me on the basis of satisfactory evidence) the within instrument and acknowledged to	FIED DIXIN (here insert name and title of the person(s) whose name(s) is/are subscribed to me that he/she/they executed the same in his/her/their
entity upon behalf of which the person(s) acte	heir signature(s) on the instrument the person(s), or the ed, execute the instrument.
WITNESS my hand and official seal.	Signature Menulul Organia
	·
(Seal)	Charlene D. Dixon NOTARY PUBLIC Montgomery County, Maryland My Commission Expires 6/1/2010

Manuel Osorio	Sorio	$\frac{3/29/2007}{Date}$
STATE OF Pina Gard	6,7)))	
UNITED STATES OF AMERICA		
to me on the basis of satisfactory ex the within instrument and acknowle	vidence) to be the persedged to me that he/shen/their signature	, personally known to me (or proved on(s) whose name(s) is/are subscribed to te/they executed the same in his/her/their (s) on the instrument the person(s), or the e instrument.
WITNESS my hand and official sea	1.	
(Seal) EXPIRES S/18/2010	Signature	Mulyata Godesse
PAGES COMMING		·

10154111/60979933 v1